Rationale behind the move Novo Nordisk said the decision is part of an ongoing effort to make authentic, FDA-approved semaglutide medicines more accessible, especially to those who might otherwise turn to unsafe, compounded alternatives
This delay contrasts with tirzepatide, which is currently accessible in the United States and has recently obtained approval in Europe
Many individuals on GLP-1 therapies also have comorbidities such as hypertension, hyperlipidemia, or cardiovascular disease, with each requiring ongoing monitoring and intervention
J Med Chem 51:27012707 Grieco P, Han G, Weinberg D, Van der Ploeg LH, Hruby VJ (2002) Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6
Efficiency Adjustment (1) Background We have historically relied on survey data provided by the American Medical Association (AMA)/Specialty Society Relative Value Scale (RVS) Update Committee (referred to as the RUC) to estimate practitioner time, work intensity, and practice expense for the purpose of establishing RVUs for the codes used for payment under the PFS
Retatrutide already activates GLP-1 and GIP receptors, the same targets tirzepatide hits